{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:17:35Z","timestamp":1790363855500,"version":"4.1.0"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"IMPORTANCE<\/jats:title>Precision oncology using comprehensive genomic profiling (CGP) by next-generation sequencing is aimed at companion diagnosis and genomic profiling. The clinical utility of CGP before the standard of care (SOC) is still not resolved, and more evidence is needed.<\/jats:p><\/jats:sec>OBJECTIVE<\/jats:title>To investigate the clinical utility of next-generation CGP (FoundationOne CDx [F1CDx]) in patients with previously untreated metastatic or recurrent solid tumors.<\/jats:p><\/jats:sec>DESIGN, Setting, and Participants<\/jats:title>This multicenter, prospective, observational cohort study enrolled patients with previously untreated advanced solid tumors between May 18, 2021, and February 16, 2022, with follow-up through August 16, 2022. The study was conducted at 6 hospitals in Japan. Eligible patients were aged 20 years or older and had Eastern Cooperative Oncology Group performance status of 0 to 1 with previously untreated metastatic or recurrent cancers in the gastrointestinal or biliary tract; pancreas, lung, breast, uterus, or ovary; and malignant melanoma.<\/jats:p><\/jats:sec>EXPOSURE<\/jats:title>Comprehensive genomic profiling testing before SOC for advanced solid tumors.<\/jats:p><\/jats:sec>MAIN OUTCOMES AND MEASURES<\/jats:title>Proportion of patients with actionable or druggable genomic alterations and molecular-based recommended therapy (MBRT).<\/jats:p><\/jats:sec>RESULTS<\/jats:title>A total of 183 patients met the inclusion criteria and 180 patients (92 men [51.1%]) with a median age of 64 years (range, 23-88 years) subsequently underwent CGP (lung [n\u2009=\u200928], colon\/small intestine [n\u2009=\u200927], pancreas [n\u2009=\u200927], breast [n\u2009=\u200925], biliary tract [n\u2009=\u200920], gastric [n\u2009=\u200919], uterus [n\u2009=\u200912], esophagus [n\u2009=\u200910], ovary [n\u2009=\u20096], and skin melanoma [n\u2009=\u20096]). Data from 172 patients were available for end point analyses. Actionable alterations were found in 172 patients (100.0%; 95% CI, 97.9%-100.0%) and druggable alternations were identified in 109 patients (63.4%; 95% CI, 55.7%-70.6%). The molecular tumor board identified MBRT for 105 patients (61.0%; 95% CI, 53.3%-68.4%). Genomic alterations included in the companion diagnostics list of the CGP test were found in 49 patients (28.5%; 95% CI, 21.9%-35.9%) in a tumor-agnostic setting. After a median follow-up of 7.9 months (range, 0.5-13.2 months), 34 patients (19.8%; 95% CI, 14.1%-26.5%) received MBRT.<\/jats:p><\/jats:sec>CONCLUSIONS AND RELEVANCE<\/jats:title>The findings of this study suggest that CGP testing before SOC for patients with advanced solid tumors may be clinically beneficial to guide the subsequent anticancer therapies, including molecularly matched treatments.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.23336","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T15:33:00Z","timestamp":1689607980000},"page":"e2323336","source":"Crossref","is-referenced-by-count":55,"title":["First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities"],"prefix":"10.1001","volume":"6","author":[{"given":"Junichi","family":"Matsubara","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumi","family":"Mukai","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Kage","sequence":"additional","affiliation":[{"name":"Department of Clinical Genomics, The University of Tokyo Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutoshi","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Clinical Genomics, The University of Tokyo Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Precision Cancer Medicine, Tokyo Medical and Dental University Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadakatsu","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Precision Cancer Medicine, Tokyo Medical and Dental University Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Ebi","sequence":"additional","affiliation":[{"name":"Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Toyama University Hospital, Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahomi","family":"Tokudome","sequence":"additional","affiliation":[{"name":"Internal Medicine III, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Internal Medicine III, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Muto","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"issue":"15","key":"zoi230690r1","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1056\/NEJMra1615014","article-title":"Classification, ontology, and precision medicine.","volume":"379","author":"Haendel","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi230690r2","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1111\/cas.v113.11","article-title":"Chronological improvement in precision oncology implementation in Japan.","volume":"113","author":"Sunami","year":"2022","journal-title":"Cancer Sci"},{"issue":"11","key":"zoi230690r5","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"issue":"7","key":"zoi230690r6","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.annonc.2020.03.299","article-title":"JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.","volume":"31","author":"Yoshino","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"zoi230690r8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"issue":"11","key":"zoi230690r9","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","article-title":"C-CAT: the national datacenter for cancer genomic medicine in Japan.","volume":"12","author":"Kohno","year":"2022","journal-title":"Cancer Discov"},{"issue":"6","key":"zoi230690r10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"7","key":"zoi230690r11","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/cas.2017.108.issue-7","article-title":"Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors.","volume":"108","author":"Kou","year":"2017","journal-title":"Cancer Sci"},{"issue":"4","key":"zoi230690r12","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/cas.2019.110.issue-4","article-title":"Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study.","volume":"110","author":"Sunami","year":"2019","journal-title":"Cancer Sci"},{"issue":"5","key":"zoi230690r13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11523-022-00910-0","article-title":"Comparing survival outcomes for advanced cancer patients who received complex genomic profiling using a synthetic control arm.","volume":"17","author":"O\u2019Haire","year":"2022","journal-title":"Target Oncol"},{"issue":"1","key":"zoi230690r14","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.v9.1","article-title":"Matching methods in precision oncology: an introduction and illustrative example.","volume":"9","author":"Weymann","year":"2021","journal-title":"Mol Genet Genomic Med"},{"issue":"2","key":"zoi230690r15","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1158\/2159-8290.CD-20-1408","article-title":"Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): a phase II study evaluating an individualized treatment strategy for metastatic disease.","volume":"11","author":"Catenacci","year":"2021","journal-title":"Cancer Discov"},{"issue":"5","key":"zoi230690r16","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/annonc\/mdz080","article-title":"Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.","volume":"30","author":"Tr\u00e9dan","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi230690r17","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/cas.v112.1","article-title":"Comprehensive genomic profiling for patients with chemotherapy-na\u00efve advanced cancer.","volume":"112","author":"Kondo","year":"2021","journal-title":"Cancer Sci"},{"issue":"9","key":"zoi230690r18","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S1470-2045(22)00035-3","article-title":"Is upfront full molecular profiling needed in all patients with colorectal cancer in daily practice?","volume":"23","author":"Dienstmann","year":"2022","journal-title":"Lancet Oncol"},{"issue":"20","key":"zoi230690r19","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"zoi230690r20","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"issue":"2","key":"zoi230690r21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10147-020-01831-6","article-title":"Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1).","volume":"26","author":"Naito","year":"2021","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"zoi230690r22","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1158\/1078-0432.CCR-20-3761","article-title":"Concomitant MEK and cyclin gene alterations: implications for response to targeted therapeutics.","volume":"27","author":"Kato","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"zoi230690r23","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"zoi230690r24","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/annonc\/mdz291","article-title":"Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric\/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.","volume":"30","author":"Jhaveri","year":"2019","journal-title":"Ann Oncol"},{"issue":"20","key":"zoi230690r25","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor\u2013positive advanced breast cancer.","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi230690r26","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","article-title":"FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies.","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"zoi230690r27","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00100","article-title":"Complete response to a fibroblast growth factor receptor inhibitor in a patient with head and neck squamous cell carcinoma harboring FGF amplifications.","volume":"2","author":"Dumbrava","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"zoi230690r28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2022.02.008","article-title":"MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: a multi-centre, retrospective study.","volume":"166","author":"Salzmann","year":"2022","journal-title":"Eur J Cancer"},{"issue":"21","key":"zoi230690r29","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1158\/1078-0432.CCR-20-1825","article-title":"The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer.","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"zoi230690r30","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study.","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol"},{"issue":"15","key":"zoi230690r31","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2021.39.15_suppl.3016","article-title":"A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors.","volume":"39","author":"LoRusso","year":"2021","journal-title":"J Clin Oncol"},{"issue":"22","key":"zoi230690r32","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer.","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi230690r33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266112","article-title":"Clinical utility of comprehensive genomic profiling in Japan: result of PROFILE-F study.","volume":"17","author":"Aoyagi","year":"2022","journal-title":"PLoS One"},{"issue":"7","key":"zoi230690r34","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/s41591-020-0969-2","article-title":"Support systems to guide clinical decision-making in precision oncology: the Cancer Core Europe Molecular Tumor Board Portal.","volume":"26","author":"Tamborero","year":"2020","journal-title":"Nat Med"},{"issue":"8","key":"zoi230690r35","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children.","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi230690r36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi230690r37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study.","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi230690r38","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"zoi230690r7","year":"2022"},{"key":"zoi230690r3","unstructured":"FDA Fact Sheet CDRH\u2019s approach to tumor profiling next generation sequencing tests. Accessed November 22, 2022. https:\/\/www.fda.gov\/media\/109050\/download"},{"key":"zoi230690r4","unstructured":"Next generation sequencing (NGS) for Medicare beneficiaries with advanced cancer (CAG-00450N). November 30, 2017. Accessed May 2, 2023. https:\/\/www.cms.gov\/medicare-coverage-database\/view\/nca.aspx?ncaid=290"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2807341\/matsubara_2023_oi_230690_1688756185.70992.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T15:33:05Z","timestamp":1689607985000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2807341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.23336","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]}}}